<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the use of felbamate in 379 adults and children with refractory <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsies</z:e> in an open-label, compassionate clinical use setting </plain></SENT>
<SENT sid="1" pm="."><plain>Prior to the termination of the program, because of reports of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, 351 patients had completed 2 months of treatment with felbamate at a dose of 2400-3600 mg/day for adults or 30-45 mg/kg/day for children </plain></SENT>
<SENT sid="2" pm="."><plain>Of the 246 patients who had a diagnosis of therapy-refractory <z:e sem="disease" ids="C0014547" disease_type="Disease or Syndrome" abbrv="">localization-related epilepsy</z:e> with or without secondary generalization, 52% (126/246) achieved a <z:hpo ids='HP_0001250'>seizure</z:hpo> reduction of 50% or more, including 10% (25/246) who became <z:hpo ids='HP_0001250'>seizure</z:hpo> free </plain></SENT>
<SENT sid="3" pm="."><plain>There was no difference in response rate between adults and children </plain></SENT>
<SENT sid="4" pm="."><plain>Of the 80 patients who had a diagnosis of <z:e sem="disease" ids="C0238111" disease_type="Disease or Syndrome" abbrv="">Lennox-Gastaut syndrome</z:e> (LGS), 60% (48/80) achieved a <z:hpo ids='HP_0001250'>seizure</z:hpo> reduction of 50% or more, including 6% (5/80) who became <z:hpo ids='HP_0001250'>seizure</z:hpo> free </plain></SENT>
<SENT sid="5" pm="."><plain>Of the 25 patients with a diagnosis of <z:e sem="disease" ids="C0014548" disease_type="Disease or Syndrome" abbrv="">generalized epilepsy</z:e> (other than LGS) or undetermined <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> whether focal or generalized, 60% (15/25) achieved a <z:hpo ids='HP_0001250'>seizure</z:hpo> reduction of 50% or more, including 12% (3/24) who became <z:hpo ids='HP_0001250'>seizure</z:hpo> free </plain></SENT>
<SENT sid="6" pm="."><plain>The results of this uncontrolled study suggest that felbamate could be useful in patients with <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsies</z:e> which are refractory to other <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> drugs after careful risk-benefit assessment and consideration of <z:hpo ids='HP_0000001'>all</z:hpo> circumstances involved </plain></SENT>
</text></document>